Organization
George Mason University, Manassas, VA
7 abstracts
Abstract
Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival.Org: University of California Comprehensive Cancer Center, San Francisco, CA, University of California, San Francisco, San Francisco, CA, University of Texas MD Anderson Cancer Center, Houston, TX, UC Davis, Davis, CA, Masonic Cancer Center, Minneapolis, MN,
Abstract
Cancer care service use intensity in Medicare Advantage versus traditional Medicare.Org: Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, Memorial Sloan Kettering Cancer Center, McDermott+ Consulting, University of Minnesota, George Mason University, Manassas, VA,
Abstract
Prediction of colorectal cancer chemotherapy efficacy using machine learning applied to gene expression data.Org: George Mason University, Manassas, VA, Fairfax, VA, Vanda Pharmaceuticals,
Abstract
Validation of the PDACai signature in predicting relative benefit from frontline FOLFIRINOX (FFX) and gemcitabine/nab-paclitaxel (GA) for patients (pts) with metastatic pancreatic cancer (mPDAC).Org: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Perthera, Oregon Health & Science University, Pancreatic Cancer Action Network, Cedars-Sinai Medical Center,
Abstract
Proteomic quantification of HER-2 abundance and activation in pancreatic ductal adenocarcinoma tumor specimens using reverse phase protein array.Org: Inova Fairfax Hospital, Inova Schar Cancer Institute, Inova Health Services, Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown University, Uniformed Services University and Walter Reed National Military Medical Center,
Abstract
Use of CLIA accredited multi-omic platforms to correlate clinical significance of WES/WTS testing with functional protein/phosphoprotein drug target activity.Org: Avera Cancer Institute, Sioux Falls, SD, Theralink Technologies Inc, George Mason University, Manassas, VA,
Abstract
Interim analysis examining the feasibility of incorporating laser microdissection enrichment of tumor specimens and reverse phase protein array analysis with next generation sequencing into a molecular tumor board.Org: Inova Schar Cancer Institute, Inova Fairfax Hospital, Inova Health Services, Uniformed Services University and Walter Reed National Military Medical Center, Theralink Technologies Inc,